Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)

REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP).  This approval is specific to Nevro`s proprietary 10 kHz Therapy and differentiates Nevro`s Senza System as the only SCS system with specific labeling to treat NSRBP patients. "Patients who suffer from intractable back pain without a prior surgery have limited treatment options if they are not a candidate for surgery," said D. Keith Grossman, Chairman, Chief Executive Officer and President of Nevro.  "This FDA approval marks another milestone in Nevro`s commitment to expanding access to 10 kHz Therapy for these underserved patients.  Nevro is now the only SCS company with specific, on-label indications for treating both NSRBP and Painful Diabetic Neuropathy patients."